Skip to content
10-Q

Quarterly Report

AOXING PHARMACEUTICAL COMPANY, INC.

0001096906-16-001361

← back to feed
Filed
Feb 8, 2016 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2016 · Feb 5, 2016 76.21M sh
Short Term Debt Q2 2016 · Dec 31, 2015 $11.04M
Short Term Debt Q2 2016 · Jun 30, 2015 $12.48M
Stockholders Equity Q2 2016 · Dec 31, 2015 $18.77M
Stockholders Equity Q2 2016 · Jun 30, 2015 $11.24M
Current Liabilities Q2 2016 · Dec 31, 2015 $35.51M
Current Liabilities Q2 2016 · Jun 30, 2015 $41.24M
Current Assets Q2 2016 · Dec 31, 2015 $25.13M
Current Assets Q2 2016 · Jun 30, 2015 $21.1M
Total Assets Q2 2016 · Dec 31, 2015 $53.58M
Total Assets Q2 2016 · Jun 30, 2015 $53.04M
Shares Diluted Q2 2016 · Dec 31, 2014 57.67M sh
Shares Diluted Q2 2016 · Dec 31, 2014 57.67M sh
Capex Q2 2016 · Dec 31, 2014 $2.94M
Operating Cash Flow Q2 2016 · Dec 31, 2014 $3.37M
Eps Diluted Q2 2016 · Dec 31, 2014 $0.01
Eps Diluted Q2 2016 · Dec 31, 2014 $0.01
Eps Basic Q2 2016 · Dec 31, 2014 $0.01
Eps Basic Q2 2016 · Dec 31, 2014 $0.01
Sga Expense Q2 2016 · Dec 31, 2014 $821.01K
Sga Expense Q2 2016 · Dec 31, 2014 $1.33M
Rd Expense Q2 2016 · Dec 31, 2014 $95.6K
Rd Expense Q2 2016 · Dec 31, 2014 $203.15K
Net Income Q2 2016 · Dec 31, 2014 $601.95K
Net Income Q2 2016 · Dec 31, 2014 $599.55K
Operating Income restated Q2 2016 · Dec 31, 2014 $1.97M
Operating Income Q2 2016 · Dec 31, 2014 $3.19M
Gross Profit restated Q2 2016 · Dec 31, 2014 $4.81M
Gross Profit Q2 2016 · Dec 31, 2014 $7.98M
Cost Of Revenue Q2 2016 · Dec 31, 2014 $1.62M
Cost Of Revenue Q2 2016 · Dec 31, 2014 $3.01M